Speech Therapy for Aphasia
(SpARc Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a treatment called Speech Entrainment Therapy (SET) for individuals with non-fluent aphasia, a condition where speaking becomes difficult after a stroke. The goal is to determine the optimal duration of SET for lasting speech improvements. Participants will join one of four groups: receiving SET for 3, 4.5, or 6 weeks, or receiving no treatment. The trial seeks individuals who have experienced a left-side stroke, speak English, and are at least 6 months post-stroke. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important findings.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Speech Entrainment Therapy (SET) is a safe treatment for individuals with non-fluent aphasia, a condition affecting speech. Studies have found that participants who received SET improved their speech without serious side effects. In one study, 24 individuals with aphasia experienced increased brain activity when speaking. Previous patients demonstrated promising results, and no negative effects from the therapy itself have been reported. This suggests that SET is generally well-tolerated, though individual experiences may vary.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about Speech Entrainment Therapy (SET) for aphasia because it offers a fresh approach to speech recovery. Unlike traditional speech therapies that often focus on repetitive language exercises, SET uses rhythmic and melodic cues to help patients synchronize their speech with external patterns, potentially enhancing fluency and speech timing. This method could be particularly effective in re-establishing speech pathways in the brain, offering a promising alternative to existing therapies. Additionally, the trial is exploring different durations of SET, which could provide insights into optimizing treatment length for better outcomes.
What evidence suggests that Speech Entrainment Therapy might be an effective treatment for non-fluent aphasia?
Research has shown that Speech Entrainment Therapy (SET), which participants in this trial may receive, helps people with non-fluent aphasia speak more smoothly. Studies have demonstrated significant improvement in speaking clearly and without mistakes among those using SET. Specifically, one study found that participants improved their speech by over 20% when speaking spontaneously. SET allows patients to copy a model they see and hear, aiding in more fluent speech. This method aligns with how the brain learns, making it effective for enhancing language skills.16789
Who Is on the Research Team?
Leonardo Bonilha, MD, PhD
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
This trial is for individuals aged 21-81 who have non-fluent aphasia due to a left hemisphere stroke, can speak English, and are at least 6 months post-stroke. They must not be pregnant, have severe dysarthria or global aphasia, uncorrectable vision/hearing issues, contraindications to MRI scans, or a history of right-hemisphere strokes or chronic neurological/psychiatric diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline language testing and an MRI
Treatment
Participants receive Speech Entrainment Therapy (SET) for 3, 4.5, or 6 weeks, or no treatment for control group
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- No Therapy
- Speech Entrainment Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator